A new investigational blood test for colorectal cancer (CRC) demonstrated encouraging results in the PREEMPT CRC study, the largest trial of any blood-based CRC screening test to date. Presented at ASCO GI 2025, the study reported 79.2% sensitivity and 91.5% specificity for CRC detection among 27,010 average-risk adults. While the test met primary endpoints, its sensitivity for advanced precancerous lesions was only 12.5%, indicating the need for further optimization.
Previous ArticleAlbany Gastroenterology Associates Files Notice of Data Breach Following Unauthorized Access to Computer Network (JD Supra)
Next Article What’s behind the DeepSeek freakout? (Politico)
Keep Reading
Add A Comment